What is the official website of Lonza ?

The official website of Lonza is http://www.lonza.com.

What is Lonza's cybersecurity risk score?

Lonza has an AI-generated cybersecurity risk score of 810 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has Lonza experienced?

According to Rankiteo, Lonza currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Lonza been affected by any supply chain cyber incidents ?

According to Rankiteo, Lonza has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Lonza have SOC 2 Type 1 certification ?

According to Rankiteo, Lonza is not certified under SOC 2 Type 1.

Does Lonza have SOC 2 Type 2 certification ?

According to Rankiteo, Lonza does not hold a SOC 2 Type 2 certification.

Does Lonza comply with GDPR ?

According to Rankiteo, Lonza is not listed as GDPR compliant.

Does Lonza have PCI DSS certification ?

According to Rankiteo, Lonza does not currently maintain PCI DSS compliance.

Does Lonza comply with HIPAA ?

According to Rankiteo, Lonza is not compliant with HIPAA regulations.

Does Lonza have ISO 27001 certification ?

According to Rankiteo,Lonza is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Lonza operate in ?

Lonza operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Lonza have ?

Lonza employs approximately 18,683 people worldwide.

Does Lonza own any subsidiaries ?

Lonza presently has no subsidiaries across any sectors.

How many LinkedIn followers does Lonza have ?

Lonza's official LinkedIn profile has approximately 421,475 followers.

What is the NAICS classification code for Lonza ?

Lonza is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Lonza have a Crunchbase profile ?

No, Lonza does not have a profile on Crunchbase.

Does Lonza have a LinkedIn profile ?

Yes, Lonza maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/lonza.

How many cybersecurity incidents has Lonza experienced ?

As of June 14, 2026, Rankiteo reports that Lonza has not experienced any cybersecurity incidents.

How many peer or competitor companies does Lonza have ?

Lonza has an estimated 5,686 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Lonza

Boost Score +25 with badge (5 left)

810

/1000

Good

835

/1000

Good

Lonza Vendor Cyber Rating & Cyber Score

lonza.com

Add Your Compliance Badge

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and

Lonza A.I CyberSecurity Scoring

Scoring History

Lonza

Lonza CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Lonza Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Lonza

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Lonza in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Lonza in 2026.

Incident Types Lonza vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Lonza in 2026.

Incident History - Lonza (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Lonza Subsidiaries

Lonza

Pharmaceutical Manufacturing

Website: http://www.lonza.com

Company Size: 10,000+ employees

Lonza BioResearch SolutionsBiotechnology Research

Lonza MODA®- Informatics Solutions for QC & ManufacturingSoftwareentwicklung

Lonza Testing SolutionsBiotechnology Research

Lonza Capsules & Health IngredientsPharmaceutical Manufacturing

Loading…

Lonza Similar Companies

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Loading…

NEWS

Lonza CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

November 06, 2021 06:13 AM

Caroline Barth interview

Caroline Barth was appointed Chief Human Resources Officer and Member of the Executive Committee of Lonza in May 2020. With 25 years of experience driving...

Read Article

September 09, 2021 07:00 AM

Why investors should care about cybersecurity

Here's why investors should consider cyber preparedness in their investment decisions and how Schroders has engaged on the topic.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-12175

SUMMARY

A vulnerability was detected in CodeAstro Student Attendance Management System 1.0. Impacted is an unknown function of the file /attendance-php/Admin/createStudents.php. Performing a manipulation of the argument admissionNumber results in sql injection. Remote exploitation of the attack is possible. The exploit is now public and may be used.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 4.7)

cvss2

Base Score: 5.8

Complexity: LOW

AV:N/AC:L/Au:M/C:P/I:P/A:P

cvss3

Base Score: 4.7

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.2

REFERENCES

CVE-2026-12174

SUMMARY

A security vulnerability has been detected in D-Link DCS-935L 1.10.01. This issue affects the function snprintf of the file /web/cgi-bin/greece/rhea of the component HTTP Handler. Such manipulation of the argument data leads to format string. The attack may be launched remotely. The exploit has been disclosed publicly and may be used.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 8.8)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 7.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-12183

SUMMARY

Nefteprodukttekhnika BUK TS-G Gas Station Automation System 2.9.1 through 2.10.2 on Linux contains an Improper Authentication vulnerability (CWE-287) in the system configuration module. The /php/ajax-login.php endpoint returns userid=1 (administrator) in response to any HTTP POST request that supplies arbitrary credentials (e.g., action=dologin&login=<any_value>&pwd=<any_value>), and subsequent privileged endpoints under /php/ajax-main.php and /modules/* do not validate a server-side session. A remote unauthenticated attacker can invoke any administrative action exposed by the configuration module, including reading and modifying user rules, fuel tank gauges, fuel dispensers, relays, cash registers, bank terminals, fuel cards, price and customer displays, cash collection, and pricing rules.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:L/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-6428

SUMMARY

SQL Injection in reports/catalogue_out.pl in Koha Community Koha through 22.11.37, 23.x, 24.x before 24.11.16, 25.05.x before 25.05.11, 25.11.x before 25.11.05, 26.05.x before 26.05.01, and 26.11.x before 26.11.00 allows an authenticated staff user with the Reports module flag to read arbitrary data from the Koha application database via the Filter URL parameter when the Criteria parameter matches /branchcode/. The vulnerable sink in sub calculate concatenates the unmodified Filter request parameter directly into a LIKE clause of the auxiliary $strsth2 statement and executes it via DBI without bound parameters: my $f = @$filters[0]; $f =~ s/\*/%/g; $strsth2 .= " AND $column LIKE '$f' "; This enables error-based SQL injection (e.g., via EXTRACTVALUE) and full read access to sensitive tables including borrowers (password hashes, 2FA secrets, PII), borrower_password_recovery, api_keys, and sessions. Proof of concept (error-based, single request): GET /cgi-bin/koha/reports/catalogue_out.pl?do_it=1&output=screen&Limit=10&Criteria=branchcode&Filter=x'+AND+EXTRACTVALUE(1,CONCAT(0x7e,VERSION(),0x7c,USER(),0x7c,DATABASE(),0x7e))--+- Cookie: CGISESSID=<LIBRARIAN_SESSION> The response body contains the DBI exception leaking the MariaDB version, database user, client IP, and database name, after which arbitrary data can be paged out using LIMIT n,1 / SUBSTRING(...). The vulnerable sink was introduced in commit 6bb77ae3e4 (2008-07-09); CVE-2015-4633 patched the same class in sibling files but did not generalise the fix to reports/catalogue_out.pl. Fixed in Koha 22.11.38, 24.11.16, 25.05.11, 25.11.05, 26.05.01, and 26.11.00 by replacing the raw concatenation with a parameterised placeholder.

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 7.6)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:N/A:P

cvss3

Base Score: 7.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:L/A:L

cvss4

Base Score: 5.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:N/VC:H/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:Y/R:X/V:C/RE:X/U:Amber

Impact Score

4.7

Exploitability

2.8

REFERENCES

CVE-2026-5513

SUMMARY

The Online Scheduling and Appointment Booking System – Bookly plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the 'bookly-customer-full-name' cookie in versions up to, and including, 27.2 due to insufficient input sanitization and output escaping. This makes it possible for unauthenticated attackers to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page. Exploitation requires 'Remember personal information in cookies' setting to be enabled (disabled by default).

Published

Date2026-06-13

Updated

Date2026-06-13

RISK INFORMATION (Score: 7.2)

cvss3

Base Score: 7.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:L/I:L/A:N

Impact Score

2.7

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…